AGN Allergan plc Ordinary Shares

+1.14  (1%)
Previous Close 219.52
Open 219.76
Price To book 1.05
Market Cap 74.11B
Shares 335,867,000
Volume 1,667,221
Short Ratio 2.69
Av. Daily Volume 2,669,820

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced March 20, 2017.
Correction of moderate to severe facial wrinkles and folds
Phase 3 trial to be initiated 2H 2017.
Cortisol Analog
Dry Eye disease
Phase 2 top-line data due 2H 2017.
Brimo DDS
Atrophic Age-related macular degeneration (AMD)
Phase 2b data due 2018.
Crohn's disease
Phase 3 enrollment to be completed 2H 2017.
Androgenic Alopecia
Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Phase 3 data due 2018.
Major depressive disorder (MDD)
Phase 2b trial to be initiated 2H 2017.
RORγt agonist
sNDA filing acceptance announced March 8, 2017. PDUFA date not noted.
Schizophrenia/ Negative symptoms
Phase 3 data released March 27 2017 - primary endpoints met. NDA filing due 2H 2017.
Severe acne vulgaris
Phase 2b top-line data due 2018.
Prophylaxis (migraine)
Phase 3 initiated July 2016. Data due 2018.
Acute (migraine)
Phase 3 to be initiated 2H 2017.
Diabetic Gastroparesis
Phase 3 initiated October 2016. Data due early 2019.
Major depressive disorder (MDD)
Phase 3 data released January 18, 2017 - endpoints met. NDA filing due 2H 2017.
ESMYA (Venus II)
Uterine Fibroids
Phase 3 to be initiated 2H 2017.
Cenicriviroc (CVC)
Nonalcoholic steatohepatitis (NASH)
Phase 3 trial to be initiated 2H 2017.
Diabetic macular edema (DME)
Phase 3 data due 2018.
Age-related macular degeneration (AMD)
sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI)
Approved January 19, 2017.
Oxymetazoline HCl cream 1.0%
Facial Erythema (Redness) Associated with Rosacea
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
sNDA accepted January 4, 2017. PDUFA estimate September 4, 2017.
Prevention of pregnancy
BLA filed November 15, 2016. BsUFA date September 14, 2017.
ABP 215
Biosimilar candidate to Avastin (bevacizumab)

Latest News

  1. Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch RHOFADE™ (Oxymetazoline HCL) Cream, 1%
  2. Allergan Announces Pricing of Public Offering of Senior Notes to Refinance Existing Debt
  3. The biggest CEO pay raises and pay cuts of 2016
  4. Has Allergan's Pullback Run Its Course?
  5. Allergan Funding SCS -- Moody's assigns Baa3 to Allergan's euro notes; stable outlook
  6. These Big Drug Stocks May Cure the Trump Blues
  7. Allergan Announces Commencement of Proposed Public Offering of Senior Notes to Refinance Existing Debt
  8. 3 Drug Stocks Billionaire Money Managers Dumped Big-Time in the First Quarter
  9. European stocks edge higher as U.S. political commotion subsides
  10. Valeant Pharmaceuticals: Intrigued…Really?
  11. Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA
  12. Allergan's Irritable Bowel Drug Viberzi Approved in Canada
  13. Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss
  14. Valeant and Actavis agree to stay litigation relating to Valeant's top-selling drug Xifaxan
  15. Is Editas Facing a New Reality in CRISPR Land?
  16. Cramer: Carl Icahn Was Right to Sell Apple at $95
  17. Biotech Movers: Akebia, Editas, Novavax
  18. Allergan's Eyepowerment™ Campaign Releases Survey Revealing the Importance of Eye Language and the Crucial Role it Plays in Our Communications
  19. VIBERZI™ Now Approved in Canada for patients with irritable bowel syndrome with diarrhea (IBS-D)